GLP-1 Genetics: Why Do They Work Better for Some People
Author
glp winnerDate Published
- Twitter
- Facebook
- LinkedIn
- Instagram
- Copy Link
New genetics research from 2026 shows that small differences in a handful of genes can change how much weight you lose on a GLP-1 medication, how much nausea you feel, and how well your blood sugar responds. Genetics is one piece of a bigger puzzle that also includes dose, how long you have been on treatment, what you eat, how you move, your sleep, and your stress.
If you started Ozempic, Wegovy, Mounjaro, or Zepbound and watched a friend drop weight quickly while your scale barely moved, it is easy to feel like something is wrong with you. Nothing is wrong with you. People respond to GLP-1 medications at very different rates, and researchers are finally starting to understand why. Your experience is real, and there are real reasons behind it.
Who This Helps
This is for you if you are on Ozempic, Wegovy, Mounjaro, Zepbound, or a compounded GLP-1 medication and you are wondering why your results do not match what you see online or what your friend is experiencing. It is also for anyone thinking about starting a GLP-1 medication who wants to set realistic expectations before day one.
What Does the New GLP-1 Genetics Research Actually Show?
The 23andMe Study on GLP-1 Weight Loss and Side Effects
In April 2026, researchers at the 23andMe Research Institute published the largest genetics study of GLP-1 users to date in the journal Nature. They looked at 27,885 people who had taken a GLP-1 medication and compared their DNA with how much weight they lost and how much nausea and vomiting they felt (Su et al., Nature 2026).
They found a common variant near the GLP-1 receptor gene, called rs10305420, that predicts a little more weight loss. Each copy of the variant was linked to about three-quarters of a kilogram of extra weight loss on top of the average. About four in ten people of European or Middle Eastern ancestry carry at least one copy.
They also found a variant in a related gene called GIPR, called rs1800437, that makes some people more likely to feel nausea or vomiting on Mounjaro or Zepbound, but not on Ozempic or Wegovy. That is the first clear sign that a gene can affect how you tolerate one GLP-1 medication without affecting how you tolerate another (Su et al., Nature 2026).
The Stanford and ETH Zurich Study on GLP-1 Blood Sugar Response
A second study, published in March 2026 in Genome Medicine by a team at Stanford Medicine and ETH Zurich, looked at a different question: why do some people with type 2 diabetes get a much smaller blood sugar benefit from a GLP-1 medication than others? (Umapathysivam et al., Genome Medicine 2026).
They zeroed in on a gene called PAM, which helps the body make GLP-1 hormone in the first place. Two variants in this gene reduced how well GLP-1 medications lowered HbA1c, a long-term measure of blood sugar. In a meta-analysis of 1,119 people, 25% of non-carriers hit their blood sugar target, compared with 11.5% and 18.5% of carriers. About 10% of the general population carries one of these variants.
The Stanford team also showed in lab models that the variants made it harder for cells to store and release GLP-1 properly, which helps explain the smaller response (Stanford Medicine News).
What Does This Mean in Plain Language?
A GLP-1 medication tells your body to feel less hungry, to empty your stomach more slowly, and to release insulin when your blood sugar rises. Every step of that process involves proteins your body builds using instructions from your genes. If one of those instructions has a small difference, the signal can be a little stronger or a little weaker. That is what these two studies are pointing at.
Two people on the same dose of Wegovy can land in very different places at month six. One may lose 18% of their starting weight. The other may lose 7%. Both are valid outcomes. The average in the big clinical trials was about 15% at 68 weeks on Wegovy, with a wide range of responses around that number (Wilding et al., NEJM 2021 (STEP 1 trial)).
Why Does the Same GLP-1 Work Differently for Different People?
Genetics is only one part of the answer. A lot of things shape how well a GLP-1 medication works for you.
- Dose and time on medication. Most people do not hit their best result until they have worked up to the target dose and stayed there for several months. Leaving a GLP-1 medication before the titration is complete is one of the most common reasons someone feels like it is not working.
- Starting weight and body composition. People with more weight to lose often see a bigger absolute drop on the scale. People with less to lose may see a smaller drop that still represents a meaningful percentage.
- What you eat and how you eat it. GLP-1 medications lower your appetite, but they do not pick your meals. Protein, fiber, and regular meals make a real difference in how the medication feels and how your body holds on to muscle.
- Movement. Walking, strength training, and daily activity protect muscle and improve insulin sensitivity. Both of those make the medication work better over time.
- Sleep and stress. Short sleep and chronic stress raise appetite hormones and cortisol, which can partly cancel out what the medication is trying to do.
- Other medications and health conditions. Thyroid issues, certain antidepressants, steroids, and insulin can all influence weight response. A good clinician will look at your whole picture before assuming the GLP-1 is the problem.
Why Does My GLP-1 Feel Different From Week to Week?
It is also normal for the same medication at the same dose to feel different from one week to the next. Hormones, hydration, sleep, stress, sodium intake, and even the time of month can all shift how your body responds. Hormonal changes during the menstrual cycle are known to affect insulin sensitivity and appetite (Yeung et al., Am J Clin Nutr 2010).
Low hydration can make nausea and constipation feel worse, while short sleep raises the hunger hormone ghrelin and lowers the fullness hormone leptin, which can make the medication feel less effective for a few days (Taheri et al., PLoS Medicine 2004). None of this means the medication has stopped working. It means you are a real person with a real body that shifts from week to week, and the averages you see online are just that, averages.
Should You Get Genetic Testing Before Starting a GLP-1?
Not yet. The Stanford and 23andMe findings are important, but no guideline recommends genetic testing before starting a GLP-1 medication in 2026. The effects they found are real but modest, and there is no validated clinical test that changes what your doctor would prescribe today (Umapathysivam et al., Genome Medicine 2026).
The practical path right now is to start at the right dose, give the medication enough time to work, and track how you feel. If you are not seeing the response you expected after you have reached the target dose, that is the moment to revisit dose, lifestyle, and other medications with your clinician, not the moment to order a genetic test.
What Should You Do If Your GLP-1 Is Not Working?
Before deciding the medication is failing you, walk through this short list with your clinician.
- Confirm the dose. Are you at the full target dose, or still titrating up? Many people do not see their best results until they have been at the target dose for at least three months.
- Check injection technique and storage. Pen issues, expired medication, and incorrect storage can quietly reduce the dose you are actually getting.
- Look at protein and fiber intake. Low appetite can lead to skipping meals. Muscle loss and fatigue follow, and both slow down weight loss.
- Add or increase movement. Even a daily walk helps. Strength training twice a week helps more.
- Ask about switching molecules. If you are not responding to a semaglutide medication like Ozempic or Wegovy, your clinician may consider a tirzepatide medication like Mounjaro or Zepbound, which acts on two hormone pathways rather than one.
- Rule out other causes. Thyroid, PCOS, sleep apnea, medication interactions, and chronic stress can all slow results and are worth a full workup.
What About Compounded GLP-1 Medications?
If you are taking a GLP-1 compound from a licensed 503A or 503B compounding pharmacy, the same genetics and lifestyle factors apply. Individual response varies because of your biology and your daily life, not because of the pharmacy that prepared your medication (GLP Winner: 503A vs 503B pharmacies). Licensed compounded products are prepared within established regulatory rules and are a legitimate option your doctor and pharmacist can walk you through. If a compounded medication is not giving you the response you hoped for, the same checklist above applies: dose, time, food, movement, sleep, and other health conditions first.
Language to Watch For
A few phrases from the real coverage of the 2026 GLP-1 genetics research are worth reading more carefully.
- "Gene variants mean weight loss drugs don't work well for some people." The Stanford and ETH study looked at blood sugar response in people with type 2 diabetes, not weight loss, and the drop in response was partial, not total. The variants made it harder to hit an HbA1c target, not impossible (Stanford Medicine News).
- "DNA may determine how Ozempic, Wegovy work." DNA influences response, but it does not determine it. In the 23andMe study, each copy of the key variant added about three-quarters of a kilogram to weight loss. Meaningful, but not the whole story (HealthDay via U.S. News).
- "Why GLP-1s fail in some patients." The research does not show failure. It shows a range of responses and points to a few genetic contributors. Most people in the studies still lost meaningful weight or improved their blood sugar, just at different rates.
- "Genetic test could predict who responds to Ozempic." No clinical genetic test is approved or recommended for GLP-1 response in 2026. The studies point toward a future possibility, not a current product.
Final Takeaway
Two major 2026 studies confirmed what many patients have been feeling all along: people respond to GLP-1 medications at different rates, and some of that difference is written in their genes. The 23andMe team found a variant near the GLP-1 receptor that nudges weight loss up, and a GIPR variant that changes how people tolerate Mounjaro and Zepbound specifically (Su et al., Nature 2026). The Stanford and ETH team found variants in a gene called PAM that reduce how well GLP-1 medications lower blood sugar (Umapathysivam et al., Genome Medicine 2026).
Genetics is a real piece of the picture. It is not the whole picture. Dose, time on medication, food, movement, sleep, stress, and other health conditions all matter. If your results are not matching what you see online, you are not broken. You are a specific person with a specific biology, and the right response is usually a calm conversation with your clinician about what to adjust first, not a jump to a new medication or a genetic test.
If you enjoy posts like these, you can subscribe to receive newsletter updates.
Sources
Keep Reading
The difference between 503A and 503B compounding pharmacies, why it matters, and how to stay safe when getting GLP-1 compounded treatments.
Early trials of gene-silencing drugs plus GLP-1s show promising fat loss, but big questions remain. Here is what the science suggests so far.
Which GLP-1 medications are FDA-approved for weight management vs diabetes? Clear labels, approved uses, and common misconceptions explained.
Curated by
